NewAmsterdam Pharma Co. NV Hits New 52-Week High of $28.61

NewAmsterdam Pharma Co. NV has reached a significant milestone by hitting a new 52-week high of USD 28.61 on September 26, 2025. This achievement underscores the company's notable performance in the pharmaceuticals and biotechnology sector, particularly as it has recorded a remarkable 44.82% increase over the past year. In comparison, the S&P 500 has shown a gain of 15.64% during the same period, highlighting NewAmsterdam's strong market position within its industry.
With a market capitalization of USD 2,826 million, NewAmsterdam operates as a small-cap company. Despite its growth, the company remains in a loss-making position, reflected in its negative price-to-earnings ratio and return on equity of -17.87%. The stock's price-to-book ratio stands at 3.63, indicating how the market values the company's equity relative to its book value. Additionally, the company has a debt-to-equity ratio of -0.95, suggesting a unique financial structure. Overall, NewAmsterdam Pharma Co. NV's recent performance marks a noteworthy achievement in its ongoing development within the competitive pharmaceutical landscape.